Collectively, these studies suggest that the role of the AR signaling pathway in prostate cancer progression is more complicated than expected, because AR collaborating TFs are entangled with each other and have differing effects on AR activity depending on testosterone levels and the duration of anti-androgen drug treatment. The gene discussed is AR; the disease is prostate carcinoma.